Ann: Imugene Presentation to Bell Potter Conference, page-100

I didn't invest in IMU because of HER-Vaxx but the last clinical update released by them nearly 2 years ago was good as I recall @slick questioning it early in the morning when the announcement was released and posters told him to stick to TA lol. You kept mentioning the HER-Vaxx data is poor, why is the data poor.....maybe you should have contacted Tobias????

Frontline vaccination with the B-cell peptide compound HER-Vaxx (IMU-131), combined with standard-of-care chemotherapy induces high levels of HER2-specific antibodies mediating ADCC and intracellular phosphorylation inhibition resulting in overall survival benefit in patients with HER2+ metastatic or advanced gastric/GEJ adenocarcinoma – Final results from Phase II/HERIZON study